Event features Prime's Health Outcomes team

Forbes

FDA approved BiTEs: Brand name Generic name Route Target Indication First FDA indication approval date Blincyto Blinatumomab IV anti-CD19 / anti-CD3 Acute lymphocytic leukemia 12/3/2014 Columvi...

Based on the clinical trial, there are certain expectations for how long patients can anticipate seeing the benefits of treatment. The median duration of response was 11.6 months (95% CI, 4.4 to...